Biocon Limited has received a credit rating reaffirmation from CRISIL Ratings Limited, maintaining its strong creditworthiness profile. The pharmaceutical company informed stock exchanges about this development as part of its regulatory disclosure obligations under SEBI regulations.

Credit Rating Details

CRISIL has reaffirmed Biocon's credit ratings across its bank facilities, demonstrating confidence in the company's financial stability and repayment capacity. The rating action covers the company's total bank loan facilities of ₹250.00 crores.

Regulatory Compliance

The rating reaffirmation was disclosed pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about material events that could impact investor decisions.

Biocon has made the rating information available on both CRISIL's official website and the company's corporate website at www.biocon.com , ensuring transparency and easy access for stakeholders.

Significance of Rating Reaffirmation

The CRISIL AA/Stable rating indicates high safety regarding timely servicing of financial obligations, with very low credit risk. The stable outlook suggests that the rating is unlikely to change in the near term. The A1+ short-term rating reflects the highest degree of safety regarding timely payment of short-term debt obligations.

This rating reaffirmation reinforces Biocon's strong financial position in the pharmaceutical sector and provides confidence to lenders and investors about the company's creditworthiness and ability to meet its financial commitments.

Biocon Limited , a prominent player in the biopharmaceutical industry, has announced a major strategic acquisition that will make Biocon Biologics Limited (BBL) its wholly-owned subsidiary. The company has also received credit rating reaffirmation from ICRA Limited, maintaining its strong financial standing.

Major Acquisition Announcement

Biocon has announced its plan to acquire minority stakes held by Mylan Inc., Serum Institute Life Sciences, Tata Capital, and Activ Pine in BBL. The transaction details are outlined below:

Funding Structure

The acquisition will be funded through a carefully structured approach:

Strategic Rationale

The acquisition is expected to deliver significant strategic benefits:

• Corporate Structure Simplification: Eliminates holding company discount for Biocon
• Operational Control: Full control over largest revenue contributor (58% of consolidated revenues)
• Synergy Realization: Expected benefits across manufacturing, procurement, and global distribution
• Debt Restructuring: Edelweiss structured debt to be repaid by January 31, 2026

Credit Rating Reaffirmation

ICRA Limited has reaffirmed Biocon's credit ratings for long-term/short-term unallocated facilities:

Financial Impact Assessment

ICRA's analysis indicates the transaction values BBL at $5.50 billion equity value ($6.60 billion enterprise value). Key financial implications include:

• Leverage Improvement: Consolidated leverage expected to reduce as structured debt gets repaid
• Liquidity Management: Critical monitoring of CP repayment following successful QIP
• Debt Metrics: Adjusted net debt unlikely to alter materially as QIP proceeds are earmarked

Corporate Governance

Biocon Limited has fulfilled its regulatory obligations by informing stock exchanges about these developments under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The information has been filed with both BSE Limited and National Stock Exchange of India Limited.

Market Positioning

The acquisition strengthens Biocon's position in the biosimilars market, with BBL having received approval for 11 biosimilars across regulated and emerging markets. The company plans to launch five additional biosimilars, further expanding its product portfolio and market reach.

This strategic move represents a significant step in Biocon's evolution, positioning the company for enhanced operational efficiency and improved financial metrics while maintaining strong credit ratings.